びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場2018-2022

Technavioが発行した調査報告書(IRTNTR23893)
◆英語タイトル:Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2018-2022
◆商品コード:IRTNTR23893
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年10月20日
◆ページ数:110
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場について調査・分析し、市場概要、市場環境、びまん性大B細胞リンパ腫(DLBCL)治療薬市場規模、製品別(小分子、生物製剤)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。主な分析対象企業は、F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Pfizer, Spectrum Pharmaceuticals, などです。
・エグゼクティブサマリー
・調査範囲・調査手法
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場概要
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場環境
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場動向
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場規模
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:業界構造分析
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:製品別(小分子、生物製剤)
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:地域別市場規模・分析
・びまん性大B細胞リンパ腫(DLBCL)治療薬の北米市場規模・予測
・びまん性大B細胞リンパ腫(DLBCL)治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・びまん性大B細胞リンパ腫(DLBCL)治療薬のアジア太平洋市場規模・予測
・びまん性大B細胞リンパ腫(DLBCL)治療薬の主要国分析
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:意思決定フレームワーク
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:成長要因、課題
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:競争環境
・びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About Diffuse Large B-Cell Lymphoma
DLBCL is a cancer of B-lymphocytes. It is the most common type of NHL among adults. It is an aggressive (fast-growing), complex, and difficult-to-treat form of NHL, which refers to a group of cancers of the lymphatic system.
Technavio’s analysts forecast the Global DLBCL Therapeutics Market to grow at a CAGR of 7.64% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the DLBCL therapeutics market. To calculate the market size, the report considers the revenue generated from the application of DLBCL therapeutics across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, DLBCL therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Pfizer
• Spectrum Pharmaceuticals
Market driver
• Increasing incidences of DLBCL
• For a full, detailed list, view our report

Market challenge
• High cost of treatment
• For a full, detailed list, view our report

Market trend
• Technological advances
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2017-2022
• Biologics – Market size and forecast 2017-2022
• Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Technological advances
• Increasing patient support programs
• Strategic alliances
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Pfizer
• Spectrum Pharmaceuticals
PART 16: APPENDIX
• List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global NHL therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global DLBCL therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global DLBCL therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Late-stage pipeline molecules for treatment of DLBCL 2017-2018
Exhibit 20: Global DLBCL therapeutics market by product – Market share 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: Global DLBCL therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global DLBCL therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global DLBCL therapeutics market by biologics – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global DLBCL therapeutics market by biologics – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Global DLBCL therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: DLBCL therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: DLBCL therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: DLBCL therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: DLBCL therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: DLBCL therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: DLBCL therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: F. Hoffmann-La Roche – Overview
Exhibit 46: F. Hoffmann-La Roche – Business segments
Exhibit 47: F. Hoffmann-La Roche – Organizational developments
Exhibit 48: F. Hoffmann-La Roche – Geographic focus
Exhibit 49: F. Hoffmann-La Roche – Segment focus
Exhibit 50: F. Hoffmann-La Roche – Key offerings
Exhibit 51: F. Hoffmann-La Roche – Key customers
Exhibit 52: Merck Sharp & Dohme – Overview
Exhibit 53: Merck Sharp & Dohme – Business segments
Exhibit 54: Merck Sharp & Dohme – Organizational developments
Exhibit 55: Merck Sharp & Dohme – Geographic focus
Exhibit 56: Merck Sharp & Dohme – Segment focus
Exhibit 57: Merck Sharp & Dohme – Key offerings
Exhibit 58: Merck Sharp & Dohme – Key customers
Exhibit 59: Novartis – Overview
Exhibit 60: Novartis – Business segments
Exhibit 61: Novartis – Organizational developments
Exhibit 62: Novartis – Geographic focus
Exhibit 63: Novartis – Segment focus
Exhibit 64: Novartis – Key offerings
Exhibit 65: Novartis – Key customers
Exhibit 66: Pfizer – Overview
Exhibit 67: Pfizer – Business segments
Exhibit 68: Pfizer – Organizational developments
Exhibit 69: Pfizer – Geographic focus
Exhibit 70: Pfizer – Segment focus
Exhibit 71: Pfizer – Key offerings
Exhibit 72: Pfizer – Key customers
Exhibit 73: Spectrum Pharmaceuticals: Overview
Exhibit 74: Spectrum Pharmaceuticals – Business segments
Exhibit 75: Spectrum Pharmaceuticals – Organizational developments
Exhibit 76: Spectrum Pharmaceuticals – Geographic focus
Exhibit 77: Spectrum Pharmaceuticals – Key offerings
Exhibit 78: Spectrum Pharmaceuticals – Key customers



【掲載企業】

F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Pfizer, Spectrum Pharmaceuticals,

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ びまん性大B細胞リンパ腫(DLBCL)治療薬の世界市場2018-2022(Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2018-2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆